This disclosure provides a lipid composition and methods of use thereof. This disclosure also provides a lipid composition comprising from about 5-150 mg retatrutide or an equivalent amount of a pharmaceutically acceptable salt thereof, as an active ingredient, one or more pharmaceutically acceptable lipid excipients, and one or more solvents
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations and substances for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders; subcutaneous drug delivery agents sold as a component of pharmaceutical preparations for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders; drug delivery agents in the form of subcutaneous compounds that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; sustained or extended release drug delivery agents sold as a component of pharmaceutical preparations for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders; drug delivery agents in the form of sustained or extended release drug delivery compounds that provide sustained or extended release of the active ingredients for a wide variety of pharmaceuticals; lipid-based drug delivery agents sold as a component of pharmaceutical preparations for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders administered via subcutaneous injection; veterinary vaccines; sanitary preparations for medical use; dietetic foods adapted for medical use; food for babies; dietary supplements for human beings and animals; medical plasters; gauze and bandages for dressings; teeth filling material; dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Devices, namely, injection instruments with needles and injection instruments without needles for subcutaneous administration of drugs; devices, namely, injection instruments with needles and injection instruments without needles for parenteral administration of drugs; devices, namely, injection instruments with needles and injection instruments without needles for drug depot injection; devices, namely, injection instruments with needles and injection instruments without needles for subcutaneous drug depot injection; devices, namely, injection instruments with needles and injection instruments without needles for parenteral drug depot injection; devices, namely, injection instruments with needles and injection instruments without needles for administration of solution for injection; devices, namely, injection instruments with needles and injection instruments without needles for administration of drug depot injection; medical syringes for subcutaneous administration of drugs; medical syringes for parenteral administration of drugs; medical syringes for drug depot injection; medical syringes for subcutaneous drug depot injection; medical syringes for parenteral drug depot injection; medical syringes for administration of solutions for injection; medical syringes for administration of drug depot injection; medical syringes for injections; syringes for medical purposes; medical apparatus and instruments, namely, needles for medical purposes; dropping pipettes for medical purposes.
A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 1 2% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to compositions forming a low viscosity mixture of:
a) 20-50 wt. % of at least one diacyl glycerol;
b) 20-54 wt. % of at least one phosphatidyl choline (PC);
c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent;
d) 1 to 20 wt. % polar solvent
e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide;
f) optionally at least one antioxidant;
wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid.
The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
C07K 7/64 - Cyclic peptides containing only normal peptide links
6.
MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT
The present invention relates to mixtures comprising at least one lipid and/or at least one oil; and an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt %. The invention further relates to mixtures which are pre-formulations, methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation, and to alkyl ammonium EDTA salts as described herein.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
The disclosure provides a glass syringe or a glass cartridge, for parenterally administering, containing a lipid-based pre-formulation suitable for refrigerated storage, wherein the lipid-based pre-formulation includes 20-80 wt % of a diacyl glycerol having a fatty acid composition of at least 98% oleic acid (18:1), as determined in accordance with method C, 2.4.22 (Composition of fatty acids by gas chromatography), European Pharmacopoeia 9.0; 20-80 wt % of a phospholipid; 1-30 wt % of a solvent; and a bioactive agent.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
The present invention relates to an injectable pre-formulation comprising:
a) at least one of a mono-, di- or tri-acyl lipid and/or a tocopherol;
b) optionally at least one phospholipid;
c) at least one biocompatible, organic solvent; and
d) at least one prostacyclin analogue or a salt thereof;
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynaud's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
This disclosure provides compositions and methods for treating neuroendocrine tumors. A lipid composition comprising 20 mg of octreotide is administered to a patient once every two weeks. The lipid composition provides slow release of octreotide.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of:
a) at least one neutral diacyl lipid and/or at least one tocopherol;
b) at least one phospholipid;
c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents.
The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of:
a) at least one neutral diacyl lipid and/or at least one tocopherol;
b) at least one phospholipid;
c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents.
The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for
injection; pharmaceutical preparation for subcutaneous
injection; pharmaceutical preparations for the treatment of
endocrine diseases and disorders; pharmaceutical
preparations for the treatment of tumours; pharmaceutical
preparations for the treatment of carcinoid tumours;
pharmaceutical preparations comprising peptides for hormonal
treatment and tumour treatment; pharmaceutical preparations
for the treatment of neuroendocrine tumours; pharmaceutical
preparations for the treatment of gastro-enteropancreatic
neuroendocrine tumours; pharmaceutical preparations for the
treatment of gastrointestinal diseases and disorders;
pharmaceutical preparations for gastrointestinal bleeding
disorders; pharmaceutical preparations for the treatment of
gastrointestinal bleeding disorders; pharmaceutical
preparations for the treatment of esophageal bleeding;
pharmaceutical preparations for metabolic disorders;
pharmaceutical preparations for the treatment of acromegaly;
pharmaceutical preparations for the treatment of polycystic
liver disease; pharmaceutical preparations for the treatment
of respiratory diseases or syndrome; pharmaceutical
preparations for the treatment of respiratory distress
syndrome; pharmaceutical preparations for the treatment of
acute respiratory distress syndrome; pharmaceutical
preparations for the treatment of disorders of the autonomic
nervous system; pharmaceutical preparations intended to
block growth hormone. Devices for administration of pharmaceuticals for the
treatment of endocrine diseases and disorders; devices for
administration of pharmaceuticals for the treatment of
tumours; devices for administration of pharmaceuticals for
the treatment of carcinoid tumours; devices for
administration of pharmaceuticals comprising peptides for
hormonal treatment and tumour treatment; devices for
administration of pharmaceuticals for the treatment of
neuroendocrine tumours; devices for administration of
pharmaceuticals for the treatment of gastro-enteropancreatic
neuroendocrine tumours; devices for administration of
pharmaceuticals for the treatment of gastrointestinal
diseases and disorders; devices for administration of
pharmaceuticals for gastrointestinal bleeding disorders;
devices for administration of pharmaceuticals for the
treatment of gastrointestinal bleeding disorders; devices
for administration of pharmaceuticals for the treatment of
esophageal bleeding; devices for administration of
pharmaceuticals for metabolic disorders; devices for
administration of pharmaceuticals for the treatment of
acromegaly; devices for administration of pharmaceuticals
for the treatment of polycystic liver disease; devices for
administration of pharmaceuticals for the treatment of
respiratory diseases or syndrome; devices for administration
of pharmaceuticals for the treatment of respiratory distress
syndrome; devices for administration of pharmaceuticals for
the treatment of acute respiratory distress syndrome;
devices for administration of pharmaceuticals for the
treatment of disorders of the autonomic nervous system;
devices for administration of pharmaceuticals intended to
block growth hormone; syringes for administration of
pharmaceuticals for the treatment of endocrine diseases and
disorders; syringes for administration of pharmaceuticals
for the treatment of tumours; syringes for administration of
pharmaceuticals for the treatment of carcinoid tumours;
syringes for administration of pharmaceuticals comprising
peptides for hormonal treatment and tumour treatment;
syringes for administration of pharmaceuticals for the
treatment of neuroendocrine tumours; syringes for
administration of pharmaceuticals for the treatment of
gastro-enteropancreatic tumours; syringes for administration
of pharmaceuticals for the treatment of gastrointestinal
diseases and disorders; syringes for administration of
pharmaceuticals for gastrointestinal bleeding disorders;
syringes for administration of pharmaceuticals for the
treatment of gastrointestinal bleeding disorders; syringes
for administration of pharmaceuticals for the treatment of
esophageal bleeding; syringes for administration of
pharmaceuticals for the treatment of metabolic disorders;
syringes for administration of pharmaceuticals for the
treatment of acromegaly; syringes for administration of
pharmaceuticals for the treatment of polycystic liver
disease; syringes for administration of pharmaceuticals for
the treatment of respiratory diseases or syndrome; syringes
for administration of pharmaceuticals for the treatment of
respiratory distress syndrome; syringes for administration
of pharmaceuticals for the treatment of acute respiratory
distress syndrome; syringes for administration of
pharmaceuticals for the treatment of disorders of the
autonomic nervous system; syringes for administration of
pharmaceuticals intended to block growth hormone; pens for
administration of pharmaceuticals for the treatment of
endocrine diseases and disorders; pens for administration of
pharmaceuticals for the treatment of tumours; pens for
administration of pharmaceuticals for the treatment of
carcinoid tumours; pens for administration of
pharmaceuticals comprising peptides for hormonal treatment
and tumour treatment; pens for administration of
pharmaceuticals for the treatment of neuroendocrine tumours;
pens for administration of pharmaceuticals for the treatment
of gastro-enteropancreatic neuroendocrine tumours; pens for
administration of pharmaceuticals for the treatment of
gastrointestinal diseases and disorders; pens for
administration of pharmaceuticals for gastrointestinal
bleeding disorders; pens for administration of
pharmaceuticals for the treatment of gastrointestinal
bleeding disorders; pens for administration of
pharmaceuticals for the treatment of esophageal bleeding;
pens for administration of pharmaceuticals for metabolic
disorders; pens for administration of pharmaceuticals for
the treatment of acromegaly; pens for administration of
pharmaceuticals for the treatment of polycystic liver
disease; pens for administration of pharmaceuticals for the
treatment of respiratory diseases or syndrome; pens for
administration of pharmaceuticals for the treatment of
respiratory distress syndrome; pens for administration of
pharmaceuticals for the treatment of acute respiratory
distress syndrome; pens for administration of
pharmaceuticals for the treatment of disorders of the
autonomic nervous system; pens for administration of
pharmaceuticals intended to block growth hormone; devices
for subcutaneous administration of pharmaceuticals; devices
for parenteral administration of pharmaceuticals; devices
for injection of pharmaceutical depots; devices for
subcutaneous injection of pharmaceutical depot; devices for
parenteral injection of pharmaceutical depot; devices for
injection of injection fluids; devices for injection of
injection depot; syringes for subcutaneous administration of
pharmaceuticals; syringes for parenteral administration of
pharmaceuticals; syringes for injection of pharmaceutical
depots; syringes for subcutaneous injection of
pharmaceutical depot; syringes for parenteral injection of
pharmaceutical depot; syringes for injection of injection
fluids; syringes for injection of injection depot; syringes
for injections; syringes for medical uses; pens for
subcutaneous administration of pharmaceuticals; pens for
parenteral administration of pharmaceuticals; pens for
injection of pharmaceutical depots; pens for subcutaneous
injection of pharmaceutical depot; pens for parenteral
injection of pharmaceutical depot; pens for injection of
injection fluids; pens for injection of injection depot;
pens for injections; pens for medical uses.
The present invention relates to compositions forming a low viscosity mixture of:
a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol;
b) 20-80 wt. % of at least one phosphatidyl choline (PC);
c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent;
d) up to 20 wt. % polar solvent
e) at least one peptide active agent;
f) optionally at least one antioxidant;
wherein the ratio of components a:b is in the range 40:60 to 54:46;
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid.
The present invention relates to compositions forming a low viscosity mixture of:
a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol;
b) 20-80 wt. % of at least one phosphatidyl choline (PC);
c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent;
d) up to 20 wt. % polar solvent
e) at least one peptide active agent;
f) optionally at least one antioxidant;
wherein the ratio of components a:b is in the range 40:60 to 54:46;
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid.
The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical preparations; pharmaceutical preparations for injection; pharmaceutical preparation for subcutaneous injection; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations intended to block growth hormone.
(2) Devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; devices for administration of pharmaceuticals for the treatment of tumours; devices for administration of pharmaceuticals for the treatment of carcinoid tumours; devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of esophageal bleeding; devices for administration of pharmaceuticals for metabolic disorders; devices for administration of pharmaceuticals for the treatment of acromegaly; devices for administration of pharmaceuticals for the treatment of polycystic liver disease; devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for the treatment of metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens for administration of pharmaceuticals for the treatment of tumours; pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens for administration of pharmaceuticals for metabolic disorders; pens for administration of pharmaceuticals for the treatment of acromegaly; pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens for administration of pharmaceuticals intended to block growth hormone; devices for subcutaneous administration of pharmaceuticals; devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of injection fluids; devices for injection of injection depot; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; pens for subcutaneous administration of pharmaceuticals; pens for parenteral administration of pharmaceuticals; pens for injection of pharmaceutical depots; pens for subcutaneous injection of pharmaceutical depot; pens for parenteral injection of pharmaceutical depot; pens for injection of injection fluids; pens for injection of injection depot; pens for injections; pens for medical uses.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations for injection for the treatment of Polycystic Kidney Disease (PKD); pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastroenteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for the treatment of metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases and syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone Medical devices used for the administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical devices used for the for administration of pharmaceuticals for the treatment of tumours; medical devices used for the for administration of pharmaceuticals for the treatment of carcinoid tumours; medical devices used for the for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical devices used for the administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical devices used for the administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; medical devices used for the administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical devices used for the administration of pharmaceuticals for gastrointestinal bleeding disorders; medical devices used for the administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical devices used for the administration of pharmaceuticals for the treatment of esophageal bleeding; medical devices used for the administration of pharmaceuticals for metabolic disorders; medical devices used for the administration of pharmaceuticals for the treatment of acromegaly; medical devices used for the administration of pharmaceuticals for the treatment of polycystic liver disease; medical devices used for the administration of pharmaceuticals for the treatment of respiratory diseases and syndrome; medical devices used for the administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical devices used for the administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical devices used for the administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical devices used for the administration of pharmaceuticals intended to block growth hormone; medical syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical syringes for administration of pharmaceuticals for the treatment of tumours; medical syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; medical syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic tumours; medical syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; medical syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; medical syringes for administration of pharmaceuticals for the treatment of metabolic disorders; medical syringes for administration of pharmaceuticals for the treatment of acromegaly; medical syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; medical syringes for administration of pharmaceuticals for the treatment of respiratory diseases and syndrome; medical syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical syringes for administration of pharmaceuticals intended to block growth hormone; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of tumours; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens in the nature of microneedle dermal pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for metabolic disorders; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of acromegaly; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens in the nature of microneedle dermal pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens in the nature of microneedle dermal pens for administration of pharmaceuticals intended to block growth hormone; medical devices for subcutaneous administration of pharmaceuticals, namely infusion and injection devices; medical devices for parenteral administration of pharmaceuticals, namely infusion and injection devices; medical devices for injection of pharmaceutical depots, namely, medical fluid injectors; devices for subcutaneous injection of pharmaceutical depot, namely, medical fluid injectors; devices for parenteral injection of pharmaceutical depot; devices for injection of injection fluids; devices for injection of injection depot being pharmaceuticals; medical syringes for subcutaneous administration and injections of pharmaceuticals; medical syringes for parenteral administration and injections of pharmaceuticals; medical syringes for injection of pharmaceutical depots; medical syringes for subcutaneous injection of pharmaceutical depot; medical syringes for parenteral injection of pharmaceutical depot; medical syringes for injections of injection fluids; medical syringes for injection of injection depot; medical syringes for injections; medical syringes for medical uses; pens in the nature of microneedle dermal pens for subcutaneous administration of pharmaceuticals; pens in the nature of microneedle dermal pens for parenteral administration of pharmaceuticals; pens in the nature of microneedle dermal pens for injection of pharmaceutical depots; pens in the nature of microneedle dermal pens for subcutaneous injection of pharmaceutical depot; pens in the nature of microneedle dermal pens for parenteral injection of pharmaceutical depot; pens in the nature of microneedle dermal pens for injection of injection fluids; pens in the nature of microneedle dermal pens for injection of injection depot; pens in the nature of microneedle dermal pens for injections; pens in the nature of microneedle dermal pens for medical uses
A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention further provides a controlled-release composition formed by administration of such an injectable liquid composition to a, preferably human, subject. The invention also provides a method of administration of buprenorphine to a subject comprising injecting such a liquid composition and a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and/or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and/or cocaine withdrawal by injecting such a liquid composition.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
This disclosure provides compositions and methods for treating acromegaly. The lipid composition comprises about 10 or about 20 mg of octreotide or a pharmaceutically acceptable salt thereof for use in treating acromegaly, wherein the lipid composition is administered to the patient once every 28 +/- 7 days. The method of treating acromegaly comprises administering to a patient in need thereof a lipid composition comprising 10 or 20 mg of octreotide or a pharmaceutically acceptable salt thereof, wherein the lipid composition is administered to the patient once every 28 +/- 7 days.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for injection; pharmaceutical preparation for subcutaneous injection; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations intended to block growth hormone.. Devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; devices for administration of pharmaceuticals for the treatment of tumours; devices for administration of pharmaceuticals for the treatment of carcinoid tumours; devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of esophageal bleeding; devices for administration of pharmaceuticals for metabolic disorders; devices for administration of pharmaceuticals for the treatment of acromegaly; devices for administration of pharmaceuticals for the treatment of polycystic liver disease; devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for the treatment of metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens for administration of pharmaceuticals for the treatment of tumours; pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens for administration of pharmaceuticals for metabolic disorders; pens for administration of pharmaceuticals for the treatment of acromegaly; pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens for administration of pharmaceuticals intended to block growth hormone; devices for subcutaneous administration of pharmaceuticals; devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of injection fluids; devices for injection of injection depot; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; pens for subcutaneous administration of pharmaceuticals; pens for parenteral administration of pharmaceuticals; pens for injection of pharmaceutical depots; pens for subcutaneous injection of pharmaceutical depot; pens for parenteral injection of pharmaceutical depot; pens for injection of injection fluids; pens for injection of injection depot; pens for injections; pens for medical uses..
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Business administrative services for medical referrals for treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder; Business administration of patient reimbursement programs for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder Providing financial information regarding medical benefits and reimbursements available for medical expenses related thereto via a website; insurance services, namely benefits verification in the nature of insurance claims administration; providing online information and financial assistance with insurance benefits and coverage for health care providers and patients for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder; Providing medical insurance benefit information for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder Educational services, namely, conducting educational programs in the field of the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefit and enrolling in benefits patient support program services. Medical services; providing medical information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals as well as the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Business administrative services for medical referrals for treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder; Business administration of patient reimbursement programs for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder Providing financial information regarding medical benefits and reimbursements available for medical expenses related thereto via a website; insurance services, namely benefits verification in the nature of insurance claims administration; providing online information and financial assistance with insurance benefits and coverage for health care providers and patients for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder; Providing medical insurance benefit information for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder Educational services, namely, conducting educational programs in the field of the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefit and enrolling in benefits patient support program services. Medical services; providing medical information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals as well as the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Business administrative services for medical referrals for treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder; Business administration of patient reimbursement programs for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder Providing financial information regarding medical benefits and reimbursements available for medical expenses related thereto via a website; insurance services, namely benefits verification in the nature of insurance claims administration; providing online information and financial assistance with insurance benefits and coverage for health care providers and patients for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder; Providing medical insurance benefit information for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder Educational services, namely, conducting educational programs in the field of the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefit and enrolling in benefits patient support program services. Medical services; providing medical information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals as well as the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorder
A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to compositions forming a low viscosity mixture of:
a) 20-50 wt. % of at least one diacyl glycerol;
b) 20-54 wt. % of at least one phosphatidyl choline (PC);
c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent;
d) 1 to 20 wt. % polar solvent
e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide;
f) optionally at least one antioxidant;
wherein the ratio of components a:b is in the range 40:60 to 54:46;
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid.
The present invention relates to compositions forming a low viscosity mixture of:
a) 20-50 wt. % of at least one diacyl glycerol;
b) 20-54 wt. % of at least one phosphatidyl choline (PC);
c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent;
d) 1 to 20 wt. % polar solvent
e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide;
f) optionally at least one antioxidant;
wherein the ratio of components a:b is in the range 40:60 to 54:46;
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid.
The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
The present invention relates to mixtures comprising:
i) at least one lipid and/or at least one oil; and
ii) an alkyl ammonium EDTA salt;
wherein the mixture has a water content in the range of 0 to 1.0 wt %.
The present invention relates to mixtures comprising:
i) at least one lipid and/or at least one oil; and
ii) an alkyl ammonium EDTA salt;
wherein the mixture has a water content in the range of 0 to 1.0 wt %.
The invention further relates to mixtures which are pre-formulations, methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation, and to alkyl ammonium EDTA salts as described herein.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/00 - Medicinal preparations characterised by special physical form
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for injection; pharmaceutical preparation for subcutaneous injection; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations intended to block growth hormone.. Devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; devices for administration of pharmaceuticals for the treatment of tumours; devices for administration of pharmaceuticals for the treatment of carcinoid tumours; devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of esophageal bleeding; devices for administration of pharmaceuticals for metabolic disorders; devices for administration of pharmaceuticals for the treatment of acromegaly; devices for administration of pharmaceuticals for the treatment of polycystic liver disease; devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens for administration of pharmaceuticals for the treatment of tumours; pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens for administration of pharmaceuticals for metabolic disorders; pens for administration of pharmaceuticals for the treatment of acromegaly; pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens for administration of pharmaceuticals intended to block growth hormone; devices for subcutaneous administration of pharmaceuticals; devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of injection fluids; devices for injection of injection depot; devices for subcutaneous administration of pharmaceuticals; devices for parenteral administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; pens for subcutaneous administration of pharmaceuticals; pens for parenteral administration of pharmaceuticals; pens for injection of pharmaceutical depots; pens for subcutaneous injection of pharmaceutical depot; pens for parenteral injection of pharmaceutical depot; pens for injection of injection fluids; pens for injection of injection depot; pens for injections; pens for medical uses..
The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of:
a) at least one neutral diacyl lipid and/or at least one tocopherol;
b) at least one phospholipid;
c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
The present invention relates to an injectable pre-formulation comprising:
a) at least one of a mono-, di- or tri-acyl lipid and/or a tocopherol;
b) optionally at least one phospholipid;
c) at least one biocompatible, organic solvent; and
d) at least one prostacyclin analogue or a salt thereof;
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynaud's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
32.
COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS
This disclosure provides compositions and methods for treating neuroendocrine tumors. A lipid composition comprising 20 mg of octreotide is administered to a patient once every two weeks. The lipid composition provides slow release of octreotide.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 35/04 - Antineoplastic agents specific for metastasis
33.
COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS
This disclosure provides compositions and methods for treating neuroendocrine tumors. A lipid composition comprising 20 mg of octreotide is administered to a patient once every two weeks. The lipid composition provides slow release of octreotide.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 35/04 - Antineoplastic agents specific for metastasis
A lipid controlled-release formulation comprising: a) about 30 to about 50 wt % of at least one diacyl glycerol; b) about 30 to about 50 wt % of at least one phosphatidylcholine; c) about 5 to about 15 wt % ethanol; d) about 0.05 to about 0.5 wt % buprenorphine. A method for the treatment of neonatal abstinence syndrome (NAS) in a human infant in need thereof, said treatment involving the steps of: administering a controlled-release formulation containing a dose of at least one opioid to said infant; wherein said controlled-release formulation provides a therapeutically effective amount of the at least one opioid for at least 4 days following administration.
wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %.
The invention further relates methods of treatment comprising administration of the pre-formulations, to pre-filled administration devices and kits containing the pre-formulations, and to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for
injection; pharmaceutical preparation for subcutaneous
injection; pharmaceutical preparations for the treatment of
endocrine diseases and disorders; pharmaceutical
preparations for the treatment of tumours; pharmaceutical
preparations for the treatment of carcinoid tumours;
pharmaceutical preparations comprising peptides for hormonal
treatment and tumour treatment; pharmaceutical preparations
for the treatment of neuroendocrine tumours; pharmaceutical
preparations for the treatment of gastro-enteropancreatic
neuroendocrine tumours; pharmaceutical preparations for the
treatment of gastrointestinal diseases and disorders;
pharmaceutical preparations for gastrointestinal bleeding
disorders; pharmaceutical preparations for the treatment of
gastrointestinal bleeding disorders; pharmaceutical
preparations for the treatment of esophageal bleeding;
pharmaceutical preparations for metabolic disorders;
pharmaceutical preparations for the treatment of acromegaly;
pharmaceutical preparations for the treatment of polycystic
liver disease; pharmaceutical preparations for the treatment
of respiratory diseases or syndrome; pharmaceutical
preparations for the treatment of respiratory distress
syndrome; pharmaceutical preparations for the treatment of
acute respiratory distress syndrome; pharmaceutical
preparations for the treatment of disorders of the autonomic
nervous system; pharmaceutical preparations intended to
block growth hormone. Devices for administration of pharmaceuticals for the
treatment of endocrine diseases and disorders; devices for
administration of pharmaceuticals for the treatment of
tumours; devices for administration of pharmaceuticals for
the treatment of carcinoid tumours; devices for
administration of pharmaceuticals comprising peptides for
hormonal treatment and tumour treatment; devices for
administration of pharmaceuticals for the treatment of
neuroendocrine tumours; devices for administration of
pharmaceuticals for the treatment of gastro-enteropancreatic
neuroendocrine tumours; devices for administration of
pharmaceuticals for the treatment of gastrointestinal
diseases and disorders; devices for administration of
pharmaceuticals for gastrointestinal bleeding disorders;
devices for administration of pharmaceuticals for the
treatment of gastrointestinal bleeding disorders; devices
for administration of pharmaceuticals for the treatment of
esophageal bleeding; devices for administration of
pharmaceuticals for metabolic disorders; devices for
administration of pharmaceuticals for the treatment of
acromegaly; devices for administration of pharmaceuticals
for the treatment of polycystic liver disease; devices for
administration of pharmaceuticals for the treatment of
respiratory diseases or syndrome; devices for administration
of pharmaceuticals for the treatment of respiratory distress
syndrome; devices for administration of pharmaceuticals for
the treatment of acute respiratory distress syndrome;
devices for administration of pharmaceuticals for the
treatment of disorders of the autonomic nervous system;
devices for administration of pharmaceuticals intended to
block growth hormone; syringes for administration of
pharmaceuticals for the treatment of endocrine diseases and
disorders; syringes for administration of pharmaceuticals
for the treatment of tumours; syringes for administration of
pharmaceuticals for the treatment of carcinoid tumours;
syringes for administration of pharmaceuticals comprising
peptides for hormonal treatment and tumour treatment;
syringes for administration of pharmaceuticals for the
treatment of neuroendocrine tumours; syringes for
administration of pharmaceuticals for the treatment of
gastro-enteropancreatic neuroendocrine tumours; syringes for
administration of pharmaceuticals for the treatment of
gastrointestinal diseases and disorders; syringes for
administration of pharmaceuticals for gastrointestinal
bleeding disorders; syringes for administration of
pharmaceuticals for the treatment of gastrointestinal
bleeding disorders; syringes for administration of
pharmaceuticals for the treatment of esophageal bleeding;
syringes for administration of pharmaceuticals for metabolic
disorders; syringes for administration of pharmaceuticals
for the treatment of acromegaly; syringes for administration
of pharmaceuticals for the treatment of polycystic liver
disease; syringes for administration of pharmaceuticals for
the treatment of respiratory diseases or syndrome; syringes
for administration of pharmaceuticals for the treatment of
respiratory distress syndrome; syringes for administration
of pharmaceuticals for the treatment of acute respiratory
distress syndrome; syringes for administration of
pharmaceuticals for the treatment of disorders of the
autonomic nervous system; syringes for administration of
pharmaceuticals intended to block growth hormone; pens for
administration of pharmaceuticals for the treatment of
endocrine diseases and disorders; pens for administration of
pharmaceuticals for the treatment of tumours; pens for
administration of pharmaceuticals for the treatment of
carcinoid tumours; pens for administration of
pharmaceuticals comprising peptides for hormonal treatment
and tumour treatment; pens for administration of
pharmaceuticals for the treatment of neuroendocrine tumours;
pens for administration of pharmaceuticals for the treatment
of gastro-enteropancreatic neuroendocrine tumours; pens for
administration of pharmaceuticals for the treatment of
gastrointestinal diseases and disorders; pens for
administration of pharmaceuticals for gastrointestinal
bleeding disorders; pens for administration of
pharmaceuticals for the treatment of gastrointestinal
bleeding disorders; pens for administration of
pharmaceuticals for the treatment of esophageal bleeding;
pens for administration of pharmaceuticals for metabolic
disorders; pens for administration of pharmaceuticals for
the treatment of acromegaly; pens for administration of
pharmaceuticals for the treatment of polycystic liver
disease; pens for administration of pharmaceuticals for the
treatment of respiratory diseases or syndrome; pens for
administration of pharmaceuticals for the treatment of
respiratory distress syndrome; pens for administration of
pharmaceuticals for the treatment of acute respiratory
distress syndrome; pens for administration of
pharmaceuticals for the treatment of disorders of the
autonomic nervous system; pens for administration of
pharmaceuticals intended to block growth hormone; devices
for subcutaneous administration of pharmaceuticals; devices
for parenteral administration of pharmaceuticals; devices
for injection of pharmaceutical depots; devices for
subcutaneous injection of pharmaceutical depot; devices for
parenteral injection of pharmaceutical depot; devices for
injection of injection fluids; devices for injection of
injection depot; devices for subcutaneous administration of
pharmaceuticals; devices for parenteral administration of
pharmaceuticals; syringes for subcutaneous administration of
pharmaceuticals; syringes for parenteral administration of
pharmaceuticals; syringes for injection of pharmaceutical
depots; syringes for subcutaneous injection of
pharmaceutical depot; syringes for parenteral injection of
pharmaceutical depot; syringes for injection of injection
fluids; syringes for injection of injection depot; syringes
for injections; syringes for medical uses; pens for
subcutaneous administration of pharmaceuticals; pens for
parenteral administration of pharmaceuticals; pens for
injection of pharmaceutical depots; pens for subcutaneous
injection of pharmaceutical depot; pens for parenteral
injection of pharmaceutical depot; pens for injection of
injection fluids; pens for injection of injection depot;
pens for injections; pens for medical uses.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for
injection; pharmaceutical preparation for subcutaneous
injection; pharmaceutical preparations for the treatment of
endocrine diseases and disorders; pharmaceutical
preparations for the treatment of tumours; pharmaceutical
preparations for the treatment of carcinoid tumours;
pharmaceutical preparations comprising peptides for hormonal
treatment and tumour treatment; pharmaceutical preparations
for the treatment of neuroendocrine tumours; pharmaceutical
preparations for the treatment of gastro-enteropancreatic
neuroendocrine tumours; pharmaceutical preparations for the
treatment of gastrointestinal diseases and disorders;
pharmaceutical preparations for gastrointestinal bleeding
disorders; pharmaceutical preparations for the treatment of
gastrointestinal bleeding disorders; pharmaceutical
preparations for the treatment of esophageal bleeding;
pharmaceutical preparations for metabolic disorders;
pharmaceutical preparations for the treatment of acromegaly;
pharmaceutical preparations for the treatment of polycystic
liver disease; pharmaceutical preparations for the treatment
of respiratory diseases or syndrome; pharmaceutical
preparations for the treatment of respiratory distress
syndrome; pharmaceutical preparations for the treatment of
acute respiratory distress syndrome; pharmaceutical
preparations for the treatment of disorders of the autonomic
nervous system; pharmaceutical preparations intended to
block growth hormone. Devices for administration of pharmaceuticals for the
treatment of endocrine diseases and disorders; devices for
administration of pharmaceuticals for the treatment of
tumours; devices for administration of pharmaceuticals for
the treatment of carcinoid tumours; devices for
administration of pharmaceuticals comprising peptides for
hormonal treatment and tumour treatment; devices for
administration of pharmaceuticals for the treatment of
neuroendocrine tumours; devices for administration of
pharmaceuticals for the treatment of gastro-enteropancreatic
neuroendocrine tumours; devices for administration of
pharmaceuticals for the treatment of gastrointestinal
diseases and disorders; devices for administration of
pharmaceuticals for gastrointestinal bleeding disorders;
devices for administration of pharmaceuticals for the
treatment of gastrointestinal bleeding disorders; devices
for administration of pharmaceuticals for the treatment of
esophageal bleeding; devices for administration of
pharmaceuticals for metabolic disorders; devices for
administration of pharmaceuticals for the treatment of
acromegaly; devices for administration of pharmaceuticals
for the treatment of polycystic liver disease; devices for
administration of pharmaceuticals for the treatment of
respiratory diseases or syndrome; devices for administration
of pharmaceuticals for the treatment of respiratory distress
syndrome; devices for administration of pharmaceuticals for
the treatment of acute respiratory distress syndrome;
devices for administration of pharmaceuticals for the
treatment of disorders of the autonomic nervous system;
devices for administration of pharmaceuticals intended to
block growth hormone; syringes for administration of
pharmaceuticals for the treatment of endocrine diseases and
disorders; syringes for administration of pharmaceuticals
for the treatment of tumours; syringes for administration of
pharmaceuticals for the treatment of carcinoid tumours;
syringes for administration of pharmaceuticals comprising
peptides for hormonal treatment and tumour treatment;
syringes for administration of pharmaceuticals for the
treatment of neuroendocrine tumours; syringes for
administration of pharmaceuticals for the treatment of
gastro-enteropancreatic neuroendocrine tumours; syringes for
administration of pharmaceuticals for the treatment of
gastrointestinal diseases and disorders; syringes for
administration of pharmaceuticals for gastrointestinal
bleeding disorders; syringes for administration of
pharmaceuticals for the treatment of gastrointestinal
bleeding disorders; syringes for administration of
pharmaceuticals for the treatment of esophageal bleeding;
syringes for administration of pharmaceuticals for metabolic
disorders; syringes for administration of pharmaceuticals
for the treatment of acromegaly; syringes for administration
of pharmaceuticals for the treatment of polycystic liver
disease; syringes for administration of pharmaceuticals for
the treatment of respiratory diseases or syndrome; syringes
for administration of pharmaceuticals for the treatment of
respiratory distress syndrome; syringes for administration
of pharmaceuticals for the treatment of acute respiratory
distress syndrome; syringes for administration of
pharmaceuticals for the treatment of disorders of the
autonomic nervous system; syringes for administration of
pharmaceuticals intended to block growth hormone; pens for
administration of pharmaceuticals for the treatment of
endocrine diseases and disorders; pens for administration of
pharmaceuticals for the treatment of tumours; pens for
administration of pharmaceuticals for the treatment of
carcinoid tumours; pens for administration of
pharmaceuticals comprising peptides for hormonal treatment
and tumour treatment; pens for administration of
pharmaceuticals for the treatment of neuroendocrine tumours;
pens for administration of pharmaceuticals for the treatment
of gastro-enteropancreatic neuroendocrine tumours; pens for
administration of pharmaceuticals for the treatment of
gastrointestinal diseases and disorders; pens for
administration of pharmaceuticals for gastrointestinal
bleeding disorders; pens for administration of
pharmaceuticals for the treatment of gastrointestinal
bleeding disorders; pens for administration of
pharmaceuticals for the treatment of esophageal bleeding;
pens for administration of pharmaceuticals for metabolic
disorders; pens for administration of pharmaceuticals for
the treatment of acromegaly; pens for administration of
pharmaceuticals for the treatment of polycystic liver
disease; pens for administration of pharmaceuticals for the
treatment of respiratory diseases or syndrome; pens for
administration of pharmaceuticals for the treatment of
respiratory distress syndrome; pens for administration of
pharmaceuticals for the treatment of acute respiratory
distress syndrome; pens for administration of
pharmaceuticals for the treatment of disorders of the
autonomic nervous system; pens for administration of
pharmaceuticals intended to block growth hormone; devices
for subcutaneous administration of pharmaceuticals; devices
for parenteral administration of pharmaceuticals; devices
for injection of pharmaceutical depots; devices for
subcutaneous injection of pharmaceutical depot; devices for
parenteral injection of pharmaceutical depot; devices for
injection of injection fluids; devices for injection of
injection depot; devices for subcutaneous administration of
pharmaceuticals; devices for parenteral administration of
pharmaceuticals; syringes for subcutaneous administration of
pharmaceuticals; syringes for parenteral administration of
pharmaceuticals; syringes for injection of pharmaceutical
depots; syringes for subcutaneous injection of
pharmaceutical depot; syringes for parenteral injection of
pharmaceutical depot; syringes for injection of injection
fluids; syringes for injection of injection depot; syringes
for injections; syringes for medical uses; pens for
subcutaneous administration of pharmaceuticals; pens for
parenteral administration of pharmaceuticals; pens for
injection of pharmaceutical depots; pens for subcutaneous
injection of pharmaceutical depot; pens for parenteral
injection of pharmaceutical depot; pens for injection of
injection fluids; pens for injection of injection depot;
pens for injections; pens for medical uses.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for
injection; pharmaceutical preparation for subcutaneous
injection; pharmaceutical preparations for the treatment of
endocrine diseases and disorders; pharmaceutical
preparations for the treatment of tumours; pharmaceutical
preparations for the treatment of carcinoid tumours;
pharmaceutical preparations comprising peptides for hormonal
treatment and tumour treatment; pharmaceutical preparations
for the treatment of neuroendocrine tumours; pharmaceutical
preparations for the treatment of gastro-enteropancreatic
neuroendocrine tumours; pharmaceutical preparations for the
treatment of gastrointestinal diseases and disorders;
pharmaceutical preparations for gastrointestinal bleeding
disorders; pharmaceutical preparations for the treatment of
gastrointestinal bleeding disorders; pharmaceutical
preparations for the treatment of esophageal bleeding;
pharmaceutical preparations for metabolic disorders;
pharmaceutical preparations for the treatment of acromegaly;
pharmaceutical preparations for the treatment of polycystic
liver disease; pharmaceutical preparations for the treatment
of respiratory diseases or syndrome; pharmaceutical
preparations for the treatment of respiratory distress
syndrome; pharmaceutical preparations for the treatment of
acute respiratory distress syndrome; pharmaceutical
preparations for the treatment of disorders of the autonomic
nervous system; pharmaceutical preparations intended to
block growth hormone. Devices for administration of pharmaceuticals for the
treatment of endocrine diseases and disorders; devices for
administration of pharmaceuticals for the treatment of
tumours; devices for administration of pharmaceuticals for
the treatment of carcinoid tumours; devices for
administration of pharmaceuticals comprising peptides for
hormonal treatment and tumour treatment; devices for
administration of pharmaceuticals for the treatment of
neuroendocrine tumours; devices for administration of
pharmaceuticals for the treatment of gastro-enteropancreatic
neuroendocrine tumours; devices for administration of
pharmaceuticals for the treatment of gastrointestinal
diseases and disorders; devices for administration of
pharmaceuticals for gastrointestinal bleeding disorders;
devices for administration of pharmaceuticals for the
treatment of gastrointestinal bleeding disorders; devices
for administration of pharmaceuticals for the treatment of
esophageal bleeding; devices for administration of
pharmaceuticals for metabolic disorders; devices for
administration of pharmaceuticals for the treatment of
acromegaly; devices for administration of pharmaceuticals
for the treatment of polycystic liver disease; devices for
administration of pharmaceuticals for the treatment of
respiratory diseases or syndrome; devices for administration
of pharmaceuticals for the treatment of respiratory distress
syndrome; devices for administration of pharmaceuticals for
the treatment of acute respiratory distress syndrome;
devices for administration of pharmaceuticals for the
treatment of disorders of the autonomic nervous system;
devices for administration of pharmaceuticals intended to
block growth hormone; syringes for administration of
pharmaceuticals for the treatment of endocrine diseases and
disorders; syringes for administration of pharmaceuticals
for the treatment of tumours; syringes for administration of
pharmaceuticals for the treatment of carcinoid tumours;
syringes for administration of pharmaceuticals comprising
peptides for hormonal treatment and tumour treatment;
syringes for administration of pharmaceuticals for the
treatment of neuroendocrine tumours; syringes for
administration of pharmaceuticals for the treatment of
gastro-enteropancreatic neuroendocrine tumours; syringes for
administration of pharmaceuticals for the treatment of
gastrointestinal diseases and disorders; syringes for
administration of pharmaceuticals for gastrointestinal
bleeding disorders; syringes for administration of
pharmaceuticals for the treatment of gastrointestinal
bleeding disorders; syringes for administration of
pharmaceuticals for the treatment of esophageal bleeding;
syringes for administration of pharmaceuticals for metabolic
disorders; syringes for administration of pharmaceuticals
for the treatment of acromegaly; syringes for administration
of pharmaceuticals for the treatment of polycystic liver
disease; syringes for administration of pharmaceuticals for
the treatment of respiratory diseases or syndrome; syringes
for administration of pharmaceuticals for the treatment of
respiratory distress syndrome; syringes for administration
of pharmaceuticals for the treatment of acute respiratory
distress syndrome; syringes for administration of
pharmaceuticals for the treatment of disorders of the
autonomic nervous system; syringes for administration of
pharmaceuticals intended to block growth hormone; pens for
administration of pharmaceuticals for the treatment of
endocrine diseases and disorders; pens for administration of
pharmaceuticals for the treatment of tumours; pens for
administration of pharmaceuticals for the treatment of
carcinoid tumours; pens for administration of
pharmaceuticals comprising peptides for hormonal treatment
and tumour treatment; pens for administration of
pharmaceuticals for the treatment of neuroendocrine tumours;
pens for administration of pharmaceuticals for the treatment
of gastro-enteropancreatic neuroendocrine tumours; pens for
administration of pharmaceuticals for the treatment of
gastrointestinal diseases and disorders; pens for
administration of pharmaceuticals for gastrointestinal
bleeding disorders; pens for administration of
pharmaceuticals for the treatment of gastrointestinal
bleeding disorders; pens for administration of
pharmaceuticals for the treatment of esophageal bleeding;
pens for administration of pharmaceuticals for metabolic
disorders; pens for administration of pharmaceuticals for
the treatment of acromegaly; pens for administration of
pharmaceuticals for the treatment of polycystic liver
disease; pens for administration of pharmaceuticals for the
treatment of respiratory diseases or syndrome; pens for
administration of pharmaceuticals for the treatment of
respiratory distress syndrome; pens for administration of
pharmaceuticals for the treatment of acute respiratory
distress syndrome; pens for administration of
pharmaceuticals for the treatment of disorders of the
autonomic nervous system; pens for administration of
pharmaceuticals intended to block growth hormone; devices
for subcutaneous administration of pharmaceuticals; devices
for parenteral administration of pharmaceuticals; devices
for injection of pharmaceutical depots; devices for
subcutaneous injection of pharmaceutical depot; devices for
parenteral injection of pharmaceutical depot; devices for
injection of injection fluids; devices for injection of
injection depot; devices for subcutaneous administration of
pharmaceuticals; devices for parenteral administration of
pharmaceuticals; syringes for subcutaneous administration of
pharmaceuticals; syringes for parenteral administration of
pharmaceuticals; syringes for injection of pharmaceutical
depots; syringes for subcutaneous injection of
pharmaceutical depot; syringes for parenteral injection of
pharmaceutical depot; syringes for injection of injection
fluids; syringes for injection of injection depot; syringes
for injections; syringes for medical uses; pens for
subcutaneous administration of pharmaceuticals; pens for
parenteral administration of pharmaceuticals; pens for
injection of pharmaceutical depots; pens for subcutaneous
injection of pharmaceutical depot; pens for parenteral
injection of pharmaceutical depot; pens for injection of
injection fluids; pens for injection of injection depot;
pens for injections; pens for medical uses.
The disclosure provides a glass syringe or a glass cartridge, for parenterally administering, containing a lipid-based pre-formulation suitable for refrigerated storage, wherein the lipid-based pre-formulation includes 20-80 wt % of a diacyl glycerol having a fatty acid composition of at least 98% oleic acid (18:1), as determined in accordance with method C, 2.4.22 (Composition of fatty acids by gas chromatography), European Pharmacopoeia 9.0; 20-80 wt % of a phospholipid; 1-30 wt % of a solvent; and a bioactive agent.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61M 5/28 - Syringe ampoules or cartridges, i.e. ampoules or cartridges provided with a needle
wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %.
The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/00 - Medicinal preparations characterised by special physical form
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations for injection for the treatment of Polycystic Kidney Disease (PKD); pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone Medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of carcinoid tumours; medical devices being infusion and injection devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of esophageal bleeding; medical devices being infusion and injection devices for administration of pharmaceuticals for metabolic disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acromegaly; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of polycystic liver disease; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical devices being infusion and injection devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; microneedle dermal pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of carcinoid tumours; microneedle dermal pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; microneedle dermal pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of esophageal bleeding; microneedle dermal pens for administration of pharmaceuticals for metabolic disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of acromegaly; microneedle dermal pens for administration of pharmaceuticals for the treatment of polycystic liver disease; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; microneedle dermal pens for administration of pharmaceuticals intended to block growth hormone; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of pharmaceuticals and medical injection fluids; devices for injection of injection depot being pharmaceuticals; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; microneedle dermal pens for subcutaneous administration of pharmaceuticals; microneedle dermal pens for parenteral administration of pharmaceuticals; microneedle dermal pens for injection of pharmaceutical depots; microneedle dermal pens for subcutaneous injection of pharmaceutical depot; microneedle dermal pens for parenteral injection of pharmaceutical depot; microneedle dermal pens for injection of injection fluids; microneedle dermal pens for injection of injection depot; microneedle dermal pens for injections; microneedle dermal pens for medical uses
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations for injection comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone; Pharmaceutical preparations for subcutaneous injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for subcutaneous injection for the treatment of tumours; pharmaceutical preparations for subcutaneous injection for the treatment of carcinoid tumours; pharmaceutical preparations for subcutaneous injection comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for subcutaneous injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for subcutaneous injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for subcutaneous injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for subcutaneous injection for gastrointestinal bleeding disorders; pharmaceutical preparations for subcutaneous injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for subcutaneous injection for the treatment of esophageal bleeding; pharmaceutical preparations for subcutaneous injection for metabolic disorders; pharmaceutical preparations for subcutaneous injection for the treatment of acromegaly; pharmaceutical preparations for subcutaneous injection for the treatment of polycystic liver disease; pharmaceutical preparations for subcutaneous injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for subcutaneous injection intended to block growth hormone; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations intended to block growth hormone
(2) Autoinjectors for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; autoinjectors for administration of pharmaceuticals for the treatment of tumours; autoinjectors for administration of pharmaceuticals for the treatment of carcinoid tumours; autoinjectors for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; autoinjectors for administration of pharmaceuticals for the treatment of neuroendocrine tumours; autoinjectors for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; autoinjectors for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; autoinjectors for administration of pharmaceuticals for gastrointestinal bleeding disorders; autoinjectors for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; autoinjectors for administration of pharmaceuticals for the treatment of esophageal bleeding; autoinjectors for administration of pharmaceuticals for metabolic disorders; autoinjectors for administration of pharmaceuticals for the treatment of acromegaly; autoinjectors for administration of pharmaceuticals for the treatment of polycystic liver disease; autoinjectors for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; autoinjectors for administration of pharmaceuticals for the treatment of respiratory distress syndrome; autoinjectors for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; autoinjectors for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; autoinjectors for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens for administration of pharmaceuticals for the treatment of tumours; pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens for administration of pharmaceuticals for metabolic disorders; pens for administration of pharmaceuticals for the treatment of acromegaly; pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens for administration of pharmaceuticals intended to block growth hormone; devices for subcutaneous administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; pens for subcutaneous administration of pharmaceuticals; pens for parenteral administration of pharmaceuticals; pens for injection of pharmaceutical depots; pens for subcutaneous injection of pharmaceutical depot; pens for parenteral injection of pharmaceutical depot; pens for injection of injection fluids; pens for injection of injection depot; pens for injections; pens for medical uses
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations for injection comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone; Pharmaceutical preparations for subcutaneous injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for subcutaneous injection for the treatment of tumours; pharmaceutical preparations for subcutaneous injection for the treatment of carcinoid tumours; pharmaceutical preparations for subcutaneous injection comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for subcutaneous injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for subcutaneous injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for subcutaneous injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for subcutaneous injection for gastrointestinal bleeding disorders; pharmaceutical preparations for subcutaneous injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for subcutaneous injection for the treatment of esophageal bleeding; pharmaceutical preparations for subcutaneous injection for metabolic disorders; pharmaceutical preparations for subcutaneous injection for the treatment of acromegaly; pharmaceutical preparations for subcutaneous injection for the treatment of polycystic liver disease; pharmaceutical preparations for subcutaneous injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for subcutaneous injection intended to block growth hormone; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations intended to block growth hormone
(2) Autoinjectors for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; autoinjectors for administration of pharmaceuticals for the treatment of tumours; autoinjectors for administration of pharmaceuticals for the treatment of carcinoid tumours; autoinjectors for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; autoinjectors for administration of pharmaceuticals for the treatment of neuroendocrine tumours; autoinjectors for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; autoinjectors for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; autoinjectors for administration of pharmaceuticals for gastrointestinal bleeding disorders; autoinjectors for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; autoinjectors for administration of pharmaceuticals for the treatment of esophageal bleeding; autoinjectors for administration of pharmaceuticals for metabolic disorders; autoinjectors for administration of pharmaceuticals for the treatment of acromegaly; autoinjectors for administration of pharmaceuticals for the treatment of polycystic liver disease; autoinjectors for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; autoinjectors for administration of pharmaceuticals for the treatment of respiratory distress syndrome; autoinjectors for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; autoinjectors for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; autoinjectors for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens for administration of pharmaceuticals for the treatment of tumours; pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens for administration of pharmaceuticals for metabolic disorders; pens for administration of pharmaceuticals for the treatment of acromegaly; pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens for administration of pharmaceuticals intended to block growth hormone; devices for subcutaneous administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; pens for subcutaneous administration of pharmaceuticals; pens for parenteral administration of pharmaceuticals; pens for injection of pharmaceutical depots; pens for subcutaneous injection of pharmaceutical depot; pens for parenteral injection of pharmaceutical depot; pens for injection of injection fluids; pens for injection of injection depot; pens for injections; pens for medical uses
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations for injection comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone; Pharmaceutical preparations for subcutaneous injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for subcutaneous injection for the treatment of tumours; pharmaceutical preparations for subcutaneous injection for the treatment of carcinoid tumours; pharmaceutical preparations for subcutaneous injection comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for subcutaneous injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for subcutaneous injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for subcutaneous injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for subcutaneous injection for gastrointestinal bleeding disorders; pharmaceutical preparations for subcutaneous injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for subcutaneous injection for the treatment of esophageal bleeding; pharmaceutical preparations for subcutaneous injection for metabolic disorders; pharmaceutical preparations for subcutaneous injection for the treatment of acromegaly; pharmaceutical preparations for subcutaneous injection for the treatment of polycystic liver disease; pharmaceutical preparations for subcutaneous injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for subcutaneous injection intended to block growth hormone; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations intended to block growth hormone
(2) Autoinjectors for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; autoinjectors for administration of pharmaceuticals for the treatment of tumours; autoinjectors for administration of pharmaceuticals for the treatment of carcinoid tumours; autoinjectors for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; autoinjectors for administration of pharmaceuticals for the treatment of neuroendocrine tumours; autoinjectors for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; autoinjectors for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; autoinjectors for administration of pharmaceuticals for gastrointestinal bleeding disorders; autoinjectors for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; autoinjectors for administration of pharmaceuticals for the treatment of esophageal bleeding; autoinjectors for administration of pharmaceuticals for metabolic disorders; autoinjectors for administration of pharmaceuticals for the treatment of acromegaly; autoinjectors for administration of pharmaceuticals for the treatment of polycystic liver disease; autoinjectors for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; autoinjectors for administration of pharmaceuticals for the treatment of respiratory distress syndrome; autoinjectors for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; autoinjectors for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; autoinjectors for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens for administration of pharmaceuticals for the treatment of tumours; pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens for administration of pharmaceuticals for metabolic disorders; pens for administration of pharmaceuticals for the treatment of acromegaly; pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens for administration of pharmaceuticals intended to block growth hormone; devices for subcutaneous administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; pens for subcutaneous administration of pharmaceuticals; pens for parenteral administration of pharmaceuticals; pens for injection of pharmaceutical depots; pens for subcutaneous injection of pharmaceutical depot; pens for parenteral injection of pharmaceutical depot; pens for injection of injection fluids; pens for injection of injection depot; pens for injections; pens for medical uses
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations for injection for the treatment of Polycystic Kidney Disease (PKD); pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone Medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of carcinoid tumours; medical devices being infusion and injection devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of esophageal bleeding; medical devices being infusion and injection devices for administration of pharmaceuticals for metabolic disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acromegaly; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of polycystic liver disease; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical devices being infusion and injection devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; microneedle dermal pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of carcinoid tumours; microneedle dermal pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; microneedle dermal pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of esophageal bleeding; microneedle dermal pens for administration of pharmaceuticals for metabolic disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of acromegaly; microneedle dermal pens for administration of pharmaceuticals for the treatment of polycystic liver disease; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; microneedle dermal pens for administration of pharmaceuticals intended to block growth hormone; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of pharmaceuticals and medical injection fluids; devices for injection of injection depot being pharmaceuticals; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; microneedle dermal pens for subcutaneous administration of pharmaceuticals; microneedle dermal pens for parenteral administration of pharmaceuticals; microneedle dermal pens for injection of pharmaceutical depots; microneedle dermal pens for subcutaneous injection of pharmaceutical depot; microneedle dermal pens for parenteral injection of pharmaceutical depot; microneedle dermal pens for injection of injection fluids; microneedle dermal pens for injection of injection depot; microneedle dermal pens for injections; microneedle dermal pens for medical uses
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations for injection for the treatment of Polycystic Kidney Disease (PKD); pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone Medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of carcinoid tumours; medical devices being infusion and injection devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of esophageal bleeding; medical devices being infusion and injection devices for administration of pharmaceuticals for metabolic disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acromegaly; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of polycystic liver disease; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical devices being infusion and injection devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; microneedle dermal pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of carcinoid tumours; microneedle dermal pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; microneedle dermal pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of esophageal bleeding; microneedle dermal pens for administration of pharmaceuticals for metabolic disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of acromegaly; microneedle dermal pens for administration of pharmaceuticals for the treatment of polycystic liver disease; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; microneedle dermal pens for administration of pharmaceuticals intended to block growth hormone; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of pharmaceuticals and medical injection fluids; devices for injection of injection depot being pharmaceuticals; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; microneedle dermal pens for subcutaneous administration of pharmaceuticals; microneedle dermal pens for parenteral administration of pharmaceuticals; microneedle dermal pens for injection of pharmaceutical depots; microneedle dermal pens for subcutaneous injection of pharmaceutical depot; microneedle dermal pens for parenteral injection of pharmaceutical depot; microneedle dermal pens for injection of injection fluids; microneedle dermal pens for injection of injection depot; microneedle dermal pens for injections; microneedle dermal pens for medical uses
The present invention relates to compositions forming a low viscosity mixture of:
The present invention relates to compositions forming a low viscosity mixture of:
a)
20-80 wt. % of at least one diacyl glycerol and/or a tocopherol;
b)
20-80 wt. % of at least one phosphatidyl choline (PC);
c)
5-20 wt. % of at least one biocompatible, organic mono-alcoholic
solvent;
d)
up to 20 wt. % polar solvent
e)
at least one peptide active agent;
f)
optionally at least one antioxidant;
wherein the ratio of components a:b is in the range 40:60 to 54:46;
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid.
The present invention relates to compositions forming a low viscosity mixture of:
a)
20-80 wt. % of at least one diacyl glycerol and/or a tocopherol;
b)
20-80 wt. % of at least one phosphatidyl choline (PC);
c)
5-20 wt. % of at least one biocompatible, organic mono-alcoholic
solvent;
d)
up to 20 wt. % polar solvent
e)
at least one peptide active agent;
f)
optionally at least one antioxidant;
wherein the ratio of components a:b is in the range 40:60 to 54:46;
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid.
The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
The present invention provides an injectable liquid formulation comprising: a) a lipid controlled-release matrix comprising at least 50% triacyl lipids; b) at least one oxygen containing organic solvent; c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention also provides a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and/or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and/or cocaine withdrawal by injecting such a liquid composition.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use, plasters; materials for dressings;
disinfectants, preparations for destroying vermin;
fungicides, herbicides; pharmaceutical preparations for the
treatment of chemical addictions; injectable pharmaceuticals
for the treatment of chemical addictions; pharmaceutical
preparations for the treatment of opiate addictions;
injectable pharmaceuticals for the treatment of opiate
addictions; pharmaceuticals for the management and relief of
pain; injectable pharmaceuticals for the management and
relief of pain; chemical preparations for pharmaceutical
purposes. Devices for subcutaneous administration of drugs; devices
for parenteral administration of drugs; devices for drug
depot injection; devices for subcutaneous drug depot
injection; devices for parenteral drug depot injection;
devices for administration of solution for injection;
devices for administration of drug depot injection; syringes
for subcutaneous administration of drugs; syringes for
parenteral administration of drugs; syringes for drug depot
injection, syringes for subcutaneous drug depot injection;
syringes for parenteral drug depot injection; syringes for
administration of solutions for injection; syringes for
administration of drug depot injection; syringes for
injections; syringes for medical purposes; medical apparatus
and instruments; needles for medical purposes; pipettes for
medical purposes; surgical apparatus and instruments.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use; plasters; materials for dressings;
disinfectants; preparations for destroying vermin;
fungicides, herbicides; pharmaceutical preparations for the
treatment of chemical addictions; injectable pharmaceuticals
for the treatment of chemical addictions; pharmaceutical
preparations for the treatment of opiate addictions;
injectable pharmaceuticals for the treatment of opiate
addictions; pharmaceuticals for the management and relief of
pain; injectable pharmaceuticals for the management and
relief of pain; chemical preparations for pharmaceutical
purposes. Devices for subcutaneous administration of drugs; devices
for parenteral administration of drugs; devices for drug
depot injection; devices for subcutaneous drug depot
injection; devices for parenteral drug depot injection;
devices for administration of solution for injection;
devices for administration of drug depot injection; syringes
for subcutaneous administration of drugs; syringes for
parenteral administration of drugs; syringes for drug depot
injection; syringes for subcutaneous drug depot injection;
syringes for parenteral drug depot injection; syringes for
administration of solutions for injection; syringes for
administration of drug depot injection; syringes for
injections; syringes for medical purposes; medical apparatus
and instruments; needles for medical purposes; pipettes for
medical purposes; surgical apparatus and instruments.
c) at least 12% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A depot precursor formulation comprising:
a) a controlled-release matrix;
b) at least oxygen containing organic solvent;
c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base.
Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A lipid controlled-release formulation comprising: a) about 30 to about 50 wt% of at least one diacyl glycerol; b) about 30 to about 50 wt% of at least one phosphatidylcholine; c) about 5 to about 15 wt% ethanol; d) about 0.05 to about 0.5 wt% buprenorphine. A method for the treatment of neonatal abstinence syndrome (NAS) in a human infant in need thereof, said treatment involving the steps of: administering a controlled-release formulation containing a dose of at least one opioid to said infant; wherein said controlled-release formulation provides a therapeutically effective amount of the at least one opioid for at least 4 days following administration.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %.
The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
Described herein are injection devices suitable for lipid controlled release formulations, particularly automatic injection devices suitable for self-administration by a subject, as well as to methods of treatment and dosage regimes utilising such devices
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base.
Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
59.
Mixtures and formulations comprising an alkyl ammonium EDTA salt
The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt %. The invention further relates to mixtures which are pre-formulations, methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation, and to alkyl ammonium EDTA salts as described herein.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to compositions comprising: (a) a biodegradable polymer; (c) an alkyl ammonium EDTA salt comprising an anion of ethylenediaminetetraacetic acid or an analogue thereof, dissolved or dispersed in said biodegradable polymer; and (d) an active agent dissolved or dispersed in said biodegradable polymer; wherein the composition has a water content in the range of 0 to 5.0 wt%. The invention further relates to methods of treatment comprising administration of such compositions, to pre-filled administration devices and kits containing the compositions, or which can be used to produce such compositions, to the use of an alkylammonium EDTA salt to reduce the decomposition of the polymer component(s) and/or active agent(s) contained within the composition.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use; adhesive plasters; materials for
dressings; disinfectants; preparations for destroying
vermin; fungicides, herbicides; pharmaceutical preparations
for the treatment of abuse of chemical substances;
injectable pharmaceutical preparations for the treatment of
abuse of chemical substances; pharmaceutical preparations
for the treatment of abuse of opiates; injectable
pharmaceutical preparations for the treatment of abuse of
opiates; pharmaceutical preparations for the treatment and
relief of pain; injectable pharmaceutical preparations for
the treatment and relief of pain. Advertising; advertising; sales promotion for others;
business management; business administration; office
functions; commercial information and advice for consumers
in the choice of products and services; commercial lobbying
services; retail services for pharmaceutical, veterinary and
sanitary preparations and medical supplies.
62.
Formulations containing a somatostatin receptor agonist
wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %.
The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to an injectable pre-formulation comprising: a) at least one of a mono-, di-, or tri-acyl lipid and/or a tocopherol; b) optionally at least one phospholipid; c) at least one biocompatible, organic solvent; and d) at least one prostacyclin analogue or a salt thereof; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynard's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use; plasters; materials for dressings;
disinfectants; preparations for destroying vermin;
fungicides, herbicides; pharmaceutical preparations for the
treatment of chemical addictions; injectable pharmaceuticals
for the treatment of chemical addictions; pharmaceutical
preparations for the treatment of opiate addictions;
injectable pharmaceuticals for the treatment of opiate
addictions; pharmaceuticals for the management and relief of
pain; injectable pharmaceuticals for the management and
relief of pain. Devices for subcutaneous administration of drugs; devices
for parenteral administration of drugs; devices for drug
depot injection; devices for subcutaneous drug depot
injection; devices for parenteral drug depot injection;
devices for administration of solution for injection;
devices for administration of drug depot injection; syringes
for subcutaneous administration of drugs; syringes for
parenteral administration of drugs; syringes for drug depot
injection; syringes for subcutaneous drug depot injection;
syringes for parenteral drug depot injection; syringes for
administration of solutions for injection; syringes for
administration of drug depot injection; syringes for
injections; syringes for medical purposes; medical apparatus
and instruments; needles for medical purposes; pipettes for
medical purposes.
Devices for subcutaneous administration of drugs; devices
for parenteral administration of drugs; devices for drug
depot injection; devices for subcutaneous drug depot
injection; devices for parenteral drug depot injection;
devices for administration of solution for injection;
devices for administration of drug depot injection; syringes
for subcutaneous administration of drugs; syringes for
parenteral administration of drugs; syringes for drug depot
injection; syringes for subcutaneous drug depot injection;
syringes for parenteral drug depot injection; syringes for
administration of solutions for injection; syringes for
administration of drug depot injection; syringes for
injections; syringes for medical purposes; medical apparatus
and instruments; needles for medical purposes.
Devices for subcutaneous administration of drugs; devices
for parenteral administration of drugs; devices for drug
depot injection; devices for subcutaneous drug depot
injection; devices for parenteral drug depot injection;
devices for administration of solution for injection;
devices for administration of drug depot injection; syringes
for subcutaneous administration of drugs; syringes for
parenteral administration of drugs; syringes for drug depot
injection; syringes for subcutaneous drug depot injection;
syringes for parenteral drug depot injection; syringes for
administration of solutions for injection; syringes for
administration of drug depot injection; syringes for
injections; syringes for medical purposes; medical apparatus
and instruments; needles for medical purposes; pipettes for
medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
Goods & Services
Pharmaceutical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic substances adapted for medical use; Adhesive plasters; Materials for dressings; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides; Pharmaceutical preparations for the treatment of abuse of chemical substances; Injectable pharmaceutical preparations for the treatment of abuse of chemical substances; Pharmaceutical preparations for the treatment of abuse of opiates; Injectable pharmaceutical preparations for the treatment of abuse of opiates; Pharmaceutical preparations for the treatment and relief of pain; Injectable pharmaceutical preparations for the treatment and relief of pain. Advertising; Advertising; Sales promotion for others; Business management; Business administration; Office functions; Commercial information and advice for consumers in the choice of products and services; Business lobbying; retail services for pharmaceutical, veterinary and sanitary preparations and medical supplies.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; plasters; materials for dressings; disinfectants; preparations for destroying vermin; fungicides, herbicides; pharmaceutical preparations for the treatment of chemical addictions; injectable pharmaceuticals for the treatment of chemical addictions; pharmaceutical preparations for the treatment of opiate addictions; injectable pharmaceuticals for the treatment of opiate addictions; pharmaceuticals for the management and relief of pain; injectable pharmaceuticals for the management and relief of pain. Devices for subcutaneous administration of drugs; devices for parenteral administration of drugs; devices for drug depot injection; devices for subcutaneous drug depot injection; devices for parenteral drug depot injection; devices for administration of solution for injection; devices for administration of drug depot injection; syringes for subcutaneous administration of drugs; syringes for parenteral administration of drugs; syringes for drug depot injection; syringes for subcutaneous drug depot injection; syringes for parenteral drug depot injection; syringes for administration of solutions for injection; syringes for administration of drug depot injection; syringes for injections; syringes for medical purposes; medical apparatus and instruments; needles for medical purposes; pipettes for medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; plasters, materials for dressings; disinfectants; preparations for destroying vermin; fungicides, herbicides. Scientific and technological services and research, development and design relating thereto; chemical laboratories; chemical research, chemical analysis; research in the fields of medicines, foods, cosmetics and biotechnology; development of technical know-how. Medical services; veterinary services; consultancy relating to medicines.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; plasters, materials for dressings; disinfectants; preparations for destroying vermin; fungicides, herbicides. Scientific and technological services and research, development and design relating thereto; chemical laboratories; chemical research, chemical analysis; research in the fields of medicines, foods, cosmetics and biotechnology; development of technical know-how. Medical services; veterinary services; consultancy relating to medicines.
71.
MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT
The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammo- nium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt%. The invention further relates to mixtures which are pre-formulations, methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation, and to alkyl ammonium EDTA salts as described herein.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt%. The invention further relates to mixtures which are pre-formulations, methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation, and to alkyl ammonium EDTA salts as described herein.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1.0 wt%. The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use; plasters, materials for dressings;
disinfectants; preparations for destroying vermin;
fungicides, herbicides. Scientific and technological services and research and
development and design relating thereto; chemical
laboratories; chemical research, chemical analysis; research
in the fields of medicines, foods, cosmetics and
biotechnology; development of technical know-how. Medical services; veterinary services; consultancy relating
to medicines.
The present invention relates to an injectable pre-formulation comprising: a) at least one of a mono-, di-or tri-acyl lipid and/or a tocopherol; b) optionally at least one phospholipid; c) at least one biocompatible, organic solvent; and d) at least one prostacyclin analogue or a salt thereof; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynaud's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/5578 - Eicosanoids, e.g. leukotrienes having a pentalene ring system, e.g. carbacyclin, iloprost
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use; plasters, materials for dressings;
disinfectants; preparations for destroying vermin;
fungicides, herbicides. Scientific and technological services and research,
development, construction and design relating thereto;
chemical laboratories; chemical research, chemical analysis;
research in the fields of medicines, foods, cosmetics and
biotechnology; development of technical know-how. Medical services; veterinary services; consultancy relating
to medicines.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use; plasters, materials for dressings;
disinfectants; preparations for destroying vermin;
fungicides, herbicides. Scientific and technological services and research,
development and design relating thereto; chemical
laboratories; chemical research, chemical analysis; research
in the fields of medicines, foods, cosmetics and
biotechnology; development of technical know-how. Medical services; veterinary services; consultancy relating
to medicines.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; plasters, materials for dressings; disinfectants; preparations for destroying vermin; fungicides, herbicides. Scientific and technological services and research, development, construction and design relating thereto; chemical laboratories; chemical research, chemical analysis; research in the fields of medicines, foods, cosmetics and biotechnology; supplying technical know-how. Medical services; veterinary services; consultancy relating to medicines.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Bleaching preparations and other substances for laundry use;
cleaning, polishing, scouring and abrasive preparations;
soaps; perfumery, essential oils, cosmetics, hair lotions;
dentifrices. Pharmaceutical, veterinary and sanitary preparations (for
medical purposes); dietetic substances adapted for medical
use, food for babies; plasters, materials for dressings;
teeth filling material; dental wax; disinfectants;
preparations for destroying vermin; fungicides, herbicides. Chemical laboratories; chemical research, chemical analysis;
research and development in the fields of medicines, foods,
cosmetics and biotechnology. Medical services; providing of know-how in the field of
pharmaceuticals. Licensing of know-how and intellectual property rights.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Bleaching preparations and other substances for laundry use;
cleaning, polishing, scouring and abrasive preparations;
soaps; perfumery, essential oils, cosmetics, hair lotions;
dentifrices. Pharmaceutical, veterinary and sanitary preparations (for
medical purposes); dietetic substances adapted for medical
use, food for babies; plasters, materials for dressings;
teeth filling material; dental wax; disinfectants;
preparations for destroying vermin; fungicides, herbicides. Chemical laboratories; chemical research, chemical analysis;
research and development in the fields of medicines, foods,
cosmetics and biotechnology. Medical services; providing of know-how in the field of
pharmaceuticals. Licensing of know-how and intellectual property rights.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Bleaching preparations and other substances for laundry use;
cleaning, polishing, scouring and abrasive preparations;
soaps; perfumery, essential oils, cosmetics, hair lotions;
dentifrices. Pharmaceutical, veterinary and sanitary preparations (for
medical purposes); dietetic substances adapted for medical
use, food for babies; plasters, materials for dressings;
teeth filling material; dental wax; disinfectants;
preparations for destroying vermin; fungicides, herbicides. Chemical laboratories; chemical research, chemical analysis;
research and development in the fields of medicines, foods,
cosmetics and biotechnology. Medical services; providing of know-how in the field of
pharmaceuticals. Licensing of know-how and intellectual property rights.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; plasters, materials for dressings; disinfectants; preparations for destroying vermin; fungicides, herbicides. Scientific and technological services and research, development, construction and design relating thereto; chemical laboratories; chemical research, chemical analysis; research in the fields of medicines, foods, cosmetics and biotechnology; supplying technical know-how. Medical services; veterinary services; consultancy relating to medicines.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; plasters, materials for dressings; disinfectants; preparations for destroying vermin; fungicides, herbicides. Scientific and technological services and research, development, construction and design relating thereto; chemical laboratories; chemical research, chemical analysis; research in the fields of medicines, foods, cosmetics and biotechnology; supplying technical know-how and/or licensing of know-how. Medical services; veterinary services; consultancy relating to medicines.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for internal use only and for
the treatment of drug addicted patients. Scientific and technological services, namely research and
design in the field of medicines.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
[ Bleaching preparations for laundry use; substances for laundry use, namely, starch, detergent and fabric softener; cleaning, polishing, scouring and abrasive preparations; non- medicated bath soap; perfumery, essential oils, cosmetics, hair lotions; dentifrices ] [ "Pharmaceutical preparations and substances for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders; subcutaneous drug delivery agents sold as a component of pharmaceutical preparations for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders; drug delivery agents in the form of subcutaneous compounds that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; sustained or extended release drug delivery agents sold as a component of pharmaceutical preparations for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders; drug delivery agents in the form of sustained or extended release drug delivery compounds that provide sustained or extended release of the active ingredients for a wide variety of pharmaceuticals; lipid-based drug delivery agents sold as a component of pharmaceutical preparations for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders administered via subcutaneous injection; veterinary vaccines; sanitary preparations for medical use; dietetic foods adapted for medical use; food for babies; medical plasters; gauze and bandages for dressings; teeth filling material; dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides" ] Chemical laboratories; chemical research, chemical analysis; research and development in the fields of medicines, foods, cosmetics and biotechnology Medical services; providing of information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals Licensing of intellectual property
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
[ Bleaching preparations for laundry use; substances for laundry use, namely, starch, detergent and fabric softener; cleaning, polishing, scouring and abrasive preparations; non- medicated bath soap; perfumery, essential oils, cosmetics, hair lotions; dentifrices ] [ Pharmaceutical preparations and substances for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders; subcutaneous drug delivery agents sold as a component of pharmaceutical preparations for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders; drug delivery agents in the form of subcutaneous compounds that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; sustained or extended release drug delivery agents sold as a component of pharmaceutical preparations for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders; drug delivery agents in the form of sustained or extended release drug delivery compounds that provide sustained or extended release of the active ingredients for a wide variety of pharmaceuticals; lipid-based drug delivery agents sold as a component of pharmaceutical preparations for the treatment of genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal, cognitive, and substance abuse related diseases and disorders administered via subcutaneous injection; veterinary vaccines; sanitary preparations for medical use; dietetic foods adapted for medical use; food for babies; medical plasters; gauze and bandages for dressings; teeth filling material; dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides ] Chemical laboratories; chemical research, chemical analysis; research and development in the fields of medicines, foods, cosmetics and biotechnology Medical services; providing of information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals Licensing of intellectual property
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring and abrasive preparations; Soaps; Perfumery, essential oils, cosmetics, hair lotions; Dentifrices. Pharmaceutical, veterinary and sanitary preparations (for medical purposes); Dietetic substances adapted for medical use, food for babies; Plasters, materials for dressings; Teeth filling material; Dental wax; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides. Chemical laboratories; Chemical research, chemical analysis; Research and development in the fields of medicines, foods, cosmetics and biotechnology. Medical services; Providing of knowhow in the field of pharmaceuticals. Licensing of knowhow and intellectual property rights.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring and abrasive preparations; Soaps; Perfumery, essential oils, cosmetics, hair lotions; Dentifrices. Pharmaceutical, veterinary and sanitary preparations (for medical purposes); Dietetic substances adapted for medical use, food for babies; Plasters, materials for dressings; Teeth filling material; Dental wax; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides. Chemical laboratories; Chemical research, chemical analysis; Research and development in the fields of medicines, foods, cosmetics and biotechnology. Medical services; Providing of knowhow in the field of pharmaceuticals. Licensing of knowhow and intellectual property rights.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring and abrasive preparations; Soaps; Perfumery, essential oils, cosmetics, hair lotions; Dentifrices. Pharmaceutical, veterinary and sanitary preparations (for medical purposes); Dietetic substances adapted for medical use, food for babies; Plasters, materials for dressings; Teeth filling material; Dental wax; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides. Chemical laboratories; Chemical research, chemical analysis; Research and development in the fields of medicines, foods, cosmetics and biotechnology. Medical services; Providing of knowhow in the field of pharmaceuticals. Licensing of knowhow and intellectual property rights.
The present invention relates to an injectable pre-formulation comprising a low viscosity mixture of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one oxygen containing organic solvent; d) at least one 5HT3 antagonist; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. Such compositions may additionally comprise polar solvents and/or further active agents such as opioid agonists and/or antagonists. Methods of treatment, particularly for management of nausea and vomiting such as for post-operative nausea and vomiting and/or therapy induced nausea and vomiting are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for internal use only and for the treatment of drug addicted patients. Scientific and technological services, namely research and design in the field of medicines.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of chemical addictions; injectable pharmaceuticals for the treatment of chemical addictions; pharmaceutical preparations for the treatment of opiate addictions; injectable pharmaceuticals for the treatment of opiate addictions; pharmaceuticals for the management and relief of pain; injectable pharmaceuticals for the management and relief of pain.
The present invention relates to pre-formulations comprising low viscosity, non- liquid crystalline, mixtures of: a) at least one ester of a sugar or sugar derivative; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid; with the proviso that the pre-formulation does not further comprise a liquid crystal hardener. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a depot composition formed by exposing pre-formulations of the invention to an aqueous fluid, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
The present invention provides an injectable liquid formulation with controlled release comprising: • a) a lipid controlled-release matrix comprising at least 50% triacyl lipids; • b) at least one oxygen containing organic solvent; • c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention also provides a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and/or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and/or cocaine withdrawal by injecting such a liquid composition.
The present invention provides an injectable liquid formulation with controlled release comprising: a) a lipid controlled-release matrix comprising at least 50% triacyl lipids; b) at least one oxygen containing organic solvent; c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention also provides a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and/or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and/or cocaine withdrawal by injecting such a liquid composition.
A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Bleaching preparations and other substances for laundry use;
cleaning, polishing, scouring and abrasive preparations;
soaps; perfumery, essential oils, cosmetics, hair lotions;
dentifrices. Pharmaceutical, veterinary and sanitary preparations (for
medical purposes); dietetic substances adapted for medical
use, food for babies; plasters, materials for dressings;
material for stopping teeth; dental wax; disinfectants;
preparations for destroying vermin; fungicides, herbicides. Chemistry services; chemical research, chemical analysis;
research and development in the fields of medicines, foods,
cosmetics and biotechnology. Medical services; providing of know-how in the field of
pharmaceuticals. Licensing of know-how and intellectual property rights.
The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
C07K 7/64 - Cyclic peptides containing only normal peptide links
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
[ Soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices ] [ Pharmaceutical preparations and substances adapted for medical use, namely, preparations for treatment of drug addicted patients, disorders in the mouth, cancer, infection, central nervous system disorders, pain, inflammation, immunological disease, hormonal disorders, growth disorders, diabetic and metabolic conditions and lipid based drug delivery agents sold as a component of various active drugs, namely, tablets, patches, capsules, intravenous, oral solutions, parenteral solutions, and suppositories for human use; veterinary preparations, namely, preparations for treatment of drug addicted patients, disorders in the mouth, cancer, infection, central nervous system disorders, pain, inflammation, immunological disease, hormonal disorders, growth disorders, diabetic and metabolic conditions and lipid based drug delivery agents sold as a component of various active drugs, namely, tablets, patches, capsules, intravenous, oral solutions, parenteral solutions, and suppositories for veterinary use, and sanitary preparations for medical purposes; food for babies; medical plasters, materials for dressings, namely, gauze and material for surgical and wound dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides ] Chemistry services, namely, chemical research and analysis, technical consulting and medical and scientific research in the pharmaceutical, [ foodstuff, cosmetical ] and biotechnical fields; chemical research, chemical analysis; research and development in the fields of medicines, [ foods, cosmetics ] and biotechnology Medical services; providing of know-how in the field of pharmaceuticals, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals [ Licensing of know-how in the field of pharmaceutical manufacture and intellectual property rights ]
The present invention relates to compositions forming a low viscosity mixture of: a. at least one diacyl glycerol and/or at least one tocopherol; b. at least one phospholipid component comprising phospholipids having i. polar head groups comprising more than 50% phosphatidyl ethanolamine, and ii. two acyl chains each independently having 16 to 20 carbons wherein at least one acyl chain has at least one unsaturation in the carbon chain, and there are no more than four unsaturations over two carbon chains; c. at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein optionally at least one bioactive agent is dissolved or dispersed in the low viscosity mixture; and wherein the pre-formulation forms, or is capable of forming, at least one non-lamellar liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/00 - Medicinal preparations characterised by special physical form
